Evotec (EVO)
(Delayed Data from NSDQ)
$3.43 USD
+0.07 (2.08%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $3.41 -0.02 (-0.58%) 7:58 PM ET
4-Sell of 5 4
C Value D Growth A Momentum C VGM
Price, Consensus and EPS Surprise
EVO 3.43 +0.07(2.08%)
Will EVO be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for EVO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for EVO
Evotec (EVO) Rises 12% on $75M Milestone Payment From BMY
EVO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for EVO
Evotec and Novo Nordisk Enter into Technology Development Partnership to Support Next-Generation Cell Therapies
Evotec, Novo Nordisk form technology development partnership for stem cell-based therapies
Evotec, Novo Nordisk forms technology development partnership for stem cell-based therapies
Evotec and Novo Nordisk sign partnership to support cell therapies
Evotec and X-Chem Collaborate to Accelerate Early-Stage Drug Discovery